Jacqueline Trouillas YOU? Author Swipe

Last 10y

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas Open

Gérald Raverot, Pia Burman, Ana Paula Abreu, Anthony P. Heaney, Leonie T. van Hulsteijn , et al. · 2025

Pituitary tumours, originating from endocrine cells of the anterior pituitary, are quite common, and in most cases well-controlled by surgery or medical treatment. However, a small subset of pituitary tumours presents with multiple local r…

Data from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Aggressive pituitary tumors are rare but difficult to manage, as there is no effective chemotherapy to restrict their growth and cause their shrinkage. Within these tumors, growth-promoting cascades, like the PI3K/mTOR pathway, appear to b…

FigureS3 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

In vitro effects of NVP-BEZ235 and NVP-BKM120 treatments on cell viability in W3 primary culture. Cell viability was measured by colorimetric assay with the CCK-8 test. Data are expressed as percentage of control (mean {plus minus} SEM). D…

FigureS1 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Tolerance of NVP-BEZ235 treatment on rats. Growth curve of rats before and during 3 weeks (A) or 6 weeks (B) of NVP-BEZ235 treatment 20 mg/kg/d, 5 days a week or control.

FigureS3 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

In vitro effects of NVP-BEZ235 and NVP-BKM120 treatments on cell viability in W3 primary culture. Cell viability was measured by colorimetric assay with the CCK-8 test. Data are expressed as percentage of control (mean {plus minus} SEM). D…

FigureS4 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Figure S4 Effect of NVP-BEZ235 and NVP-BKM120 treatments on phosphorylated p44/42 MAPK(Thr202/Tyr204) in (A) GH3 cells and (B-C) SMtTW3 tumors. (A) Treatments were performed with DMSO, NVP-BEZ235 or NVP-BKM120 at concentrations 1, 100, and…

Data from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Aggressive pituitary tumors are rare but difficult to manage, as there is no effective chemotherapy to restrict their growth and cause their shrinkage. Within these tumors, growth-promoting cascades, like the PI3K/mTOR pathway, appear to b…

FigureS2 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Tolerance of NVP-BKM120 treatment on rats. Growth curve (A) or glycemia (B) of rats before and during 4 weeks of NVP-BKM120 treatment 5 mg/kg/d, 5 days a week or control.

FigureS1 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Tolerance of NVP-BEZ235 treatment on rats. Growth curve of rats before and during 3 weeks (A) or 6 weeks (B) of NVP-BEZ235 treatment 20 mg/kg/d, 5 days a week or control.

FigureS4 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Figure S4 Effect of NVP-BEZ235 and NVP-BKM120 treatments on phosphorylated p44/42 MAPK(Thr202/Tyr204) in (A) GH3 cells and (B-C) SMtTW3 tumors. (A) Treatments were performed with DMSO, NVP-BEZ235 or NVP-BKM120 at concentrations 1, 100, and…

FigureS2 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors Open

Marie Chanal, Pascale Chevallier, Véronique Raverot, Guillaume Fonteneau, K. Lucia , et al. · 2023

Tolerance of NVP-BKM120 treatment on rats. Growth curve (A) or glycemia (B) of rats before and during 4 weeks of NVP-BKM120 treatment 5 mg/kg/d, 5 days a week or control.

Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients Open

Pia Burman, Jacqueline Trouillas, Marco Losa, Ann McCormack, Stephan Petersenn , et al. · 2022

Objective To describe clinical and pathological characteristics and treatment outcomes in a large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design Electronic survey August 2020–May 2021. Results 96% of 171 (12…

GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1 Open

Vinaya Srirangam Nadhamuni, Donato Iacovazzo, Jane Evanson, Anju Sahdev, Jacqueline Trouillas , et al. · 2021

Summary A male patient with a germline mutation in MEN1 presented at the age of 18 with classical features of gigantism. Previously, he had undergone resection of an insulin-secreting pancreatic neuroendocrine tumour (pNET) at the age of 1…

How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020 Open

Jacqueline Trouillas, Marie‐Lise Jaffrain‐Rea, Alexandre Vasiljevic, Gérald Raverot, Federico Roncaroli , et al. · 2020

Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors (PitNET), are mostly benign, but may present various behaviors: invasive, “aggressive” and malignant with metastases. They are classified into seven morph…

Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution Open

L. Sylvia, Sofia Asioli, Süheyla Bozkurt, Olivera Casar‐Borota, Laura Chinezu , et al. · 2019

not available

Diagnosis, pathology, and management of TSH-secreting pituitary tumors. A single-center retrospective study of 20 patients from 1981 to 2014 Open

Oana-Maria Căpraru, Céline Gaillard, Alexandre Vasiljevic, Hélène Lasolle, Françoise Borson‐Chazot , et al. · 2019

Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours Open

Jacqueline Trouillas, Etienne Delgrange, Anne Wierinckx, Alexandre Vasiljevic, Emmanuel Jouanneau , et al. · 2019

The behaviour of lactotroph tumours varies between benign tumours, those cured by treatment, and that of aggressive tumours, and carcinomas with metastasis. Identification of clinical, pathological and molecular factors is essential for th…

Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability Open

Anne Wierinckx, Etienne Delgrange, Philippe Bertolino, Patrick François, Philippe Chanson , et al. · 2018

Sex-related differences have been reported in various cancers, in particular men with lactotroph tumors have a worse prognosis than women. While the underlying mechanism of this sexual dimorphism remains unclear, it has been suggested that…

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal Open

Guido Rindi, David S. Klimstra, Behnoush Abedi‐Ardekani, L. Sylvia, Fred T. Bosman , et al. · 2018

Aggressive pituitary tumours and carcinomas: two sides of the same coin? Open

Jacqueline Trouillas, Pia Burman, Ann McCormack, Stephan Petersenn, Vera Popović , et al. · 2018

The European Society of Endocrinology (ESE) survey reported on the largest cohort of 125 aggressive pituitary tumours (APT) and 40 pituitary carcinomas (PC). Whilst the survey focused on treatment effectiveness, all pathological data were …

Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET) Open

Jacqueline Trouillas, Gérald Raverot · 2018

This article refers to:HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016 Open

Ann McCormack, Olaf M. Dekkers, Stephan Petersenn, Vera Popović, Jacqueline Trouillas , et al. · 2018

Objective To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment. Design Electronic survey to ESE members Dec 2015–Nov 2…

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas Open

Gérald Raverot, Pia Burman, Ann McCormack, Anthony P. Heaney, Stephan Petersenn , et al. · 2017

Background Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurren…

Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification Open

Gérald Raverot, Emmanuelle Dantony, J. Beauvy, Alexandre Vasiljevic, Sara Mikolasek , et al. · 2017

Our data suggest that classification of PitNETs into five grades is of prognostic value to predict postoperative tumor behavior and identifies patients who have a high risk of early recurrence or progression. It therefore will allow clinic…

From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal Open

L. Sylvia, Olivera Casar‐Borota, Philippe Chanson, Etienne Delgrange, Peter Earls , et al. · 2017

The classification of neoplasms of adenohypophysial cells is misleading because of the simplistic distinction between adenoma and carcinoma, based solely on metastatic spread and the poor reproducibility and predictive value of the definit…

Transdifferentiation of Neuroendocrine Cells Open

Camille Sergeant, Christel Jublanc, Delphine Leclercq, Anne-Laure Boch, Franck Bielle , et al. · 2017

Gangliocytomas are rare and benign neuronal cell tumors, mostly found in the hypothalamic and sellar regions. Their histogenesis is still the subject of discussions. Herein we present a unique case of a pituitary gangliocytoma associated w…

Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour Open

Nikolaos Kyriakakis, Jacqueline Trouillas, Mary Dang, Julie Lynch, P E Belchetz , et al. · 2017

Summary A male patient presented at the age of 30 with classic clinical features of acromegaly and was found to have elevated growth hormone levels, not suppressing during an oral glucose tolerance test. His acromegaly was originally consi…

Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature Open

Laura Chinezu, Alexandre Vasiljevic, Jacqueline Trouillas, Marion Lapoirie, Emmanuel Jouanneau , et al. · 2016

Background Silent somatotroph tumours are growth hormone (GH) immunoreactive (IR) pituitary tumours without clinical and biological signs of acromegaly. Their better characterisation is required to improve the diagnosis. Materials and meth…

Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study Open

Donato Iacovazzo, Richard Caswell, Benjamin Bunce, Sian Jose, Bo Yuan , et al. · 2016

Somatic<i>GPR101</i>Duplication Causing X-Linked Acrogigantism (XLAG)—Diagnosis and Management Open

Celia Rodd, Maude Millette, Donato Iacovazzo, Craig E Stiles, Sayka Barry , et al. · 2016

Our patient is the first to be described with somatic microduplication leading to typical XLAG phenotype. This patient demonstrates that a negative test for Xq26.3 microduplication or GPR101 duplication on peripheral blood DNA does not exc…

Fetching topic information...